| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Cardio IQ® Diabetes and ASCVD Risk Panel with Scores
Test CodeCPT Codes
80061, 82947, 83036
Includes
Cardio IQ® Glucose
Cardio IQ® Hemoglobin A1c
Cardio IQ® Cholesterol, Total
Cardio IQ® HDL Cholesterol
Cardio IQ® Triglycerides
Cardio IQ® Non-HDL and Calculated Components
Cardio IQ® Risks and Personal Factors
If Triglyceride is >400 mg/dL, then Cardio IQ® Direct LDL will be performed at an additional charge (CPT code: 83721).
If Triglyceride is extremely elevated, >1293 mg/dL, this causes interference in the Cardio IQ® Direct LDL assay, therefore this test cannot be added.
Preferred Specimen
Patient Preparation
If a cholesterol measurement is to be performed along with Triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required.
The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid" where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
Minimum Volume
Instructions
Age: Years
Gender: M (for male) or F (for female)
Race - African American: Y (for yes) or N (for no)
Systolic Blood Pressure: mmHg
Treatment for High B.P.: Y (for yes) or N (for no)
Diabetes Status: Y (for yes) or N (for no)
Smoking Status: Y (for yes) or N (for no)
Transport Temperature
Specimen Stability
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 28 days
Whole blood
Room temperature: 7 days
Refrigerated: 7 days
Frozen: 6 months
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Methodology
Turbidimetric Inhibition Immunoassay • Spectrophotometry (SP)
Setup Schedule
Reference Range
Clinical Significance
This panel provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.
Performing Laboratory
| Quest Diagnostics Nichols Institute-San Juan Capistrano, CA |
| 33608 Ortega Highway |
| San Juan Capistrano, CA 92675-2042 |

